PDF(Pubmed)
Abstract：
OBJECTIVE: To compare the efficacy of low and moderate 131I activities in low-risk differentiated thyroid carcinoma (DTC) patients requiring postoperative thyroid remnant ablation in a real-world clinical setting.
METHODS: We retrospectively reviewed the records of 299 low-risk DTC patients (pT1-T2, Nx(0) Mx) who had undergone (near)-total thyroidectomy followed by 131I therapy, using either low (1.1 GBq) or moderate (2.2 GBq) radioiodine activities. The response to initial treatments was evaluated after 8-12 months, and patient responses were classified according to the 2015 American Thyroid Association guidelines.
RESULTS: An excellent response was observed in 274/299 (91.6%) patients, specifically, in 119/139 (85.6%) and 155/160 (96.9%) patients treated with low and moderate 131I activities, respectively (p = 0.029). A biochemically indeterminate or incomplete response was observed in seventeen (22.2%) patients treated with low 131I activities and three (1.8%) patients treated with moderate 131I activities (p = 0.001). Finally, five patients showed an incomplete structural response, among which three and two received low and moderate 131I activities, respectively (p = 0.654).
CONCLUSIONS: When 131I ablation is indicated, we encourage the use of moderate instead of low activities, in order to reach an excellent response in a significantly larger proportion of patients, including patients with the unexpected persistence of the disease.
METHODS: We retrospectively reviewed the records of 299 low-risk DTC patients (pT1-T2, Nx(0) Mx) who had undergone (near)-total thyroidectomy followed by 131I therapy, using either low (1.1 GBq) or moderate (2.2 GBq) radioiodine activities. The response to initial treatments was evaluated after 8-12 months, and patient responses were classified according to the 2015 American Thyroid Association guidelines.
RESULTS: An excellent response was observed in 274/299 (91.6%) patients, specifically, in 119/139 (85.6%) and 155/160 (96.9%) patients treated with low and moderate 131I activities, respectively (p = 0.029). A biochemically indeterminate or incomplete response was observed in seventeen (22.2%) patients treated with low 131I activities and three (1.8%) patients treated with moderate 131I activities (p = 0.001). Finally, five patients showed an incomplete structural response, among which three and two received low and moderate 131I activities, respectively (p = 0.654).
CONCLUSIONS: When 131I ablation is indicated, we encourage the use of moderate instead of low activities, in order to reach an excellent response in a significantly larger proportion of patients, including patients with the unexpected persistence of the disease.
摘要：
目的：比较低和中度131I活性在低风险分化型甲状腺癌（DTC）患者术后甲状腺残余消融中的疗效。
方法：我们回顾性回顾了299例低风险DTC患者（pT1-T2，Nx（0）Mx）的记录，这些患者进行了（近）全甲状腺切除术，然后进行了131I治疗，使用低（1.1GBq）或中等（2.2GBq）的放射性碘活性。在8-12个月后评估对初始治疗的反应，根据2015年美国甲状腺协会指南对患者的反应进行分类.
结果：在274/299（91.6％）患者中观察到了极好的反应，具体来说,在119/139（85.6％）和155/160（96.9％）接受低和中度131I活动治疗的患者中，分别（p=0.029）。在17例（22.2％）接受低131I活性治疗的患者和3例（1.8％）接受中度131I活性治疗的患者中观察到生化不确定或不完全反应（p=0.001）。最后,五名患者表现出不完全的结构反应，其中三人和两人接受了低和中等的131I活动，分别(p=0.654)。
结论：当需要进行131I消融时，我们鼓励使用适度而不是低活动，为了在更大比例的患者中达到良好的反应，包括患有这种疾病的患者。
方法：我们回顾性回顾了299例低风险DTC患者（pT1-T2，Nx（0）Mx）的记录，这些患者进行了（近）全甲状腺切除术，然后进行了131I治疗，使用低（1.1GBq）或中等（2.2GBq）的放射性碘活性。在8-12个月后评估对初始治疗的反应，根据2015年美国甲状腺协会指南对患者的反应进行分类.
结果：在274/299（91.6％）患者中观察到了极好的反应，具体来说,在119/139（85.6％）和155/160（96.9％）接受低和中度131I活动治疗的患者中，分别（p=0.029）。在17例（22.2％）接受低131I活性治疗的患者和3例（1.8％）接受中度131I活性治疗的患者中观察到生化不确定或不完全反应（p=0.001）。最后,五名患者表现出不完全的结构反应，其中三人和两人接受了低和中等的131I活动，分别(p=0.654)。
结论：当需要进行131I消融时，我们鼓励使用适度而不是低活动，为了在更大比例的患者中达到良好的反应，包括患有这种疾病的患者。
